Research programme: diabetes therapeutics - MC2 Therapeutics

Drug Profile

Research programme: diabetes therapeutics - MC2 Therapeutics

Alternative Names: RX-1

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MC2 Biotek
  • Developer MC2 Therapeutics
  • Class Small molecules
  • Mechanism of Action Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 23 Jan 2015 Research programme: diabetes therapeutics - mc2 biotek is available for licensing as of 23 Jan 2015.
  • 01 Aug 2014 Preclinical trials in Type-2 diabetes mellitus in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top